Eloxx Pharmaceuticals Posts $5.54M Q3 Net Loss, Reports $56.3M Cash

Eloxx Pharmaceuticals reported a Q3 2026 net loss of $5.54M, or $0.49 per share, with $56.3M in cash. R&D expenses rose to $4.03M from a prior-year credit of $0.25M. The company dosed the first patients in its Phase 2b Alport syndrome study and received FDA clearance for an ADPKD study. It expects topline Alport study results in mid-2027.

Original reporting
Published Nov 16, 2026, 2:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 2:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Eloxx Pharmaceuticals Posts $5.54M Q3 Net Loss, Reports $56.3M Cash — source image
Decision brief

The 30-second read

$ELOXNeutralMed
01

Why it matters

The earnings loss may pressure the stock short‑term, but regulatory clearance and trial initiation could attract long‑term interest.

02

Market read

Primary micro‑cap earnings release with material regulatory news; relevant for biotech traders.

03

What to watch

Potential partnership or licensing revenue from exaluren program not disclosed yet.

Relevance 8/10Novelty 8/10Timing: today

Background

Eloxx Pharmaceuticals reported Q3 results with a net loss and disclosed progress on two kidney‑disease trials, including FDA clearance for a Phase 2b ADPKD study.

Company-level read

Ticker impact

$ELOXNeutralHigh confidence
Context

Q3 2026 earnings release showing a $5.54M net loss and FDA clearance for a Phase 2b ADPKD study.

Expected impact

likely modest downside as market prices in the loss, offset by potential upside from trial progress

Evidence & confidence

Loss is material for a micro‑cap, but FDA clearance is a significant positive development for future valuation.

Market effects

Adds momentum to the kidney‑disease biotech niche as FDA clearances signal regulatory progress.

Limited to US‑listed biotech investors.

Minor; primarily relevant to niche biotech investors.

Counterpoint

The loss may be overstated; focus on cash runway and upcoming trial data could drive a rally.

Key entities

  • Eloxx Pharmaceuticals

    US‑listed biotech developing exaluren for kidney diseases.

  • FDA

    Granted investigational new drug clearance for Eloxx's ADPKD study.

Related articles

$ELOXMed

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Eloxx Pharmaceuticals, Inc. (ELOX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Dosed first two patients in global Phase 2b EXACT study of exaluren in nonsense mutation Alport syndrome; topline data from the 16-week placebo-controlled portion expect

$ELOXMedAI 8/10

Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Eloxx Pharmaceuticals (ELOX) reported Q3 2026 results, highlighting progress in clinical trials for exaluren in rare kidney diseases. The company dosed the first patients in a Phase 2b study for Alport syndrome and finalized a Phase 2 study for ADPKD. Eloxx had $56.3M in cash as of September 30, 2026, and expects it to last into 2028. The company also expanded its leadership team and reported a net loss of $5.5M for the quarter.

$ELOXMedAI 8/10

Eloxx receives FDA clearance for ADPKD drug trial in U.S.

Eloxx Pharmaceuticals (NASDAQ:ELOX) received FDA clearance to start a Phase 2 trial for exaluren, a treatment for autosomal dominant polycystic kidney disease (ADPKD). The EXPRESS trial will enroll 60 adults with nonsense mutations, with results expected in 2029. The FDA noted potential for Breakthrough Therapy Designation and accelerated approval. Exaluren has orphan drug designation in the U.S. and Europe. ADPKD affects 160,000-200,000 people in the U.S.

$ELOXMedAI 8/10

Eloxx finalizes phase 2 trial design for rare kidney disease

Eloxx Pharmaceuticals (ELOX) finalized its Phase 2 trial design for exaluren in treating autosomal dominant polycystic kidney disease. The global trial will enroll 60 adults, with results expected in 2029. The FDA noted potential for Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas as Chief Medical Officer. Exaluren has orphan drug designations in the U.S. and Europe.

$ELOXMedAI 8/10

Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer

Eloxx Pharmaceuticals (ELOX) finalized its EXPRESS Phase 2 study design for treating nonsense-mutation ADPKD with exaluren, expecting first patient dosing in 3Q 2027 and topline data in 1H 2029. The study will enroll 60 patients, with htTKV growth as the primary endpoint. The FDA noted that a substantial htTKV effect could support Breakthrough Therapy Designation. Eloxx also appointed T.R. Srinivas, M.D., as Chief Medical Officer.